Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Delate, Aubrey Jones, N. Clark, D. Witt (2017)
Assessment of the coding accuracy of warfarin-related bleeding events.Thrombosis research, 159
F. Ynsaurriaga, R. Peinado, J. Merodio (2014)
Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation.Future cardiology, 10 3
T. Wilke, S. Bauer, S. Mueller, T. Kohlmann, R. Bauersachs (2016)
Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature ReviewThe Patient, 10
M. Serper, E. Weinberg, Jordana Cohen, P. Reese, T. Taddei, D. Kaplan (2020)
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With AnticoagulationHepatology, 73
L. Wallentin, R. Lopes, M. Hanna, L. Thomas, A. Hellkamp, S. Nepal, E. Hylek, S. Al‐Khatib, J. Alexander, M. Alings, J. Amerena, J. Ansell, P. Aylward, J. Bartunek, P. Commerford, R. Caterina, Ç. Erol, V. Harjola, C. Held, J. Horowitz, K. Huber, S. Husted, M. Keltai, F. Lanas, Li-sheng Liu, J. McMurray, B. Oh, M. Rosenqvist, W. Rużyłło, P. Steg, D. Vinereanu, D. Xavier, C. Granger (2013)
Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial FibrillationCirculation, 127
L. Kuo, T. Chao, Chia-Jen Liu, Yenn-Jiang Lin, S. Chang, L. Lo, Yu-Feng Hu, Ta-Chuan Tuan, J. Liao, F. Chung, Tzeng-Ji Chen, G. Lip, Shih‐Ann Chen (2017)
Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6
N. Intagliata, Z. Henry, Hillary Maitland, Neeral Shah, C. Argo, P. Northup, S. Caldwell (2016)
Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional AnticoagulationDigestive Diseases and Sciences, 61
(2020)
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).European heart journal
T. Chao, C. Chiang, Yenn-Jiang Lin, S. Chang, L. Lo, Yu-Feng Hu, Ta-Chuan Tuan, J. Liao, F. Chung, Tzeng-Ji Chen, G. Lip, Shih‐Ann Chen (2018)
Evolving Changes of the Use of Oral Anticoagulants and Outcomes in Patients With Newly Diagnosed Atrial Fibrillation in Taiwan.Circulation, 138 14
Huey-Juan Lin, P. Wolf, M. Kelly‐Hayes, A. Beiser, C. Kase, E. Benjamin, R. D’Agostino (1996)
Stroke severity in atrial fibrillation. The Framingham Study.Stroke, 27 10
So-Ryoung Lee, Hyun-Jung Lee, E. Choi, Kyungdo Han, Jin-Hyung Jung, M. Cha, Seil Oh, G. Lip (2019)
Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Liver Disease.Journal of the American College of Cardiology, 73 25
H. Bucher, G. Guyatt, L. Griffith, S. Walter (1997)
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.Journal of clinical epidemiology, 50 6
CT January (2019)
10.1161/CIR.0000000000000665Circulation, 140
Daehoon Kim, Pil‐Sung Yang, E. Jang, H. Yu, Tae‐Hoon Kim, J. Uhm, Jong-Youn Kim, H. Pak, Moon‐Hyoung Lee, B. Joung, G. Lip (2018)
10‐year nationwide trends of the incidence, prevalence, and adverse outcomes of non‐valvular atrial fibrillation nationwide health insurance data covering the entire Korean populationAmerican Heart Journal, 202
G. Lee, V. Chen, C. Tan, A. Leow, W. Kong, C. Sia, N. Chew, T. Tu, B. Chan, L. Yeo, V. Sharma, B. Tan (2020)
Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonist in cerebral venous thrombosisJournal of Thrombosis and Thrombolysis, 50
C. Chiang, T. Wu, K. Ueng, T. Chao, Kuan-Cheng Chang, Chun-Chieh Wang, Yenn-Jiang Lin, W. Yin, J. Kuo, Wei-Shiang Lin, Chia-Ti Tsai, Yen‐Bin Liu, Kun-Tai Lee, Li‐Jen Lin, Lian‐Yu Lin, Kang-Ling Wang, Yi‐Jen Chen, Mien-Cheng Chen, Chen-Chuan Cheng, M. Wen, Wen-Jone Chen, Jyh‐Hong Chen, W. Lai, C. Chiou, Jiunn-lee Lin, S. Yeh, Shih‐Ann Chen (2016)
2016 Guidelines of the Taiwan Heart Rhythm Society and the Taiwan Society of Cardiology for the management of atrial fibrillation.Journal of the Formosan Medical Association = Taiwan yi zhi, 115 11
T. Wilke, A. Groth, S. Mueller, M. Pfannkuche, F. Verheyen, R. Linder, U. Maywald, R. Bauersachs, G. Breithardt (2013)
Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 15 4
S. Pearson, R. Troughton, A. Richards (2011)
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.The New England journal of medicine, 365 24
G. Hugenholtz, J. Adelmeijer, J. Meijers, R. Porte, R. Stravitz, T. Lisman (2013)
An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcomeHepatology, 58
Julian Higgins, Sally Green (2010)
Cochrane Handbook for Systematic Reviews of InterventionsInternational Coaching Psychology Review
W. Ageno, A. Gallus, A. Wittkowsky, M. Crowther, E. Hylek, G. Palareti (2012)
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest, 141 2 Suppl
R. Verbeeck (2008)
Pharmacokinetics and dosage adjustment in patients with hepatic dysfunctionEuropean Journal of Clinical Pharmacology, 64
Christopher Joos, K. Lawrence, Aubrey Jones, Stacy Johnson, D. Witt (2019)
Accuracy of ICD-10 codes for identifying hospitalizations for acute anticoagulation therapy-related bleeding events.Thrombosis research, 181
Hsin-Fu Lee, Y. Chan, Shang-Hung Chang, H. Tu, Shao‐Wei Chen, Yung-Hsin Yeh, Lung‐Sheng Wu, Chang-Fu Kuo, C. Kuo, L. See (2019)
Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial FibrillationJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8
K. Balcı, M. Balci, U. Canpolat, F. Şen, M. Akboga, Muhammed Süleymanoğlu, S. Kuyumcu, O. Maden, H. Selçuk, M. Selçuk (2015)
Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillationAnatolian Journal of Cardiology, 16
A. Holbrook, J. Pereira, R. Labiris, H. Mcdonald, J. Douketis, M. Crowther, P. Wells (2005)
Systematic overview of warfarin and its drug and food interactions.Archives of internal medicine, 165 10
D. Kubitza, A. Roth, M. Becka, Abir Alatrach, A. Halabi, H. Hinrichsen, W. Mueck (2013)
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.British journal of clinical pharmacology, 76 1
R. Mehran, S. Rao, Deepak Bhatt, C. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J. Sabik, D. Cutlip, M. Krucoff, E. Ohman, P. Steg, H. White (2011)
Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research ConsortiumCirculation, 123
Géric Maura, C. Billionnet, J. Drouin, A. Weill, A. Neumann, A. Pariente (2019)
Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011–2016BMJ Open, 9
Gregory Roth, G. Mensah, C. Johnson, G. Addolorato, E. Ammirati, L. Baddour, N. Barengo, A. Beaton, E. Benjamin, Catherine Benziger, A. Bonny, Michael Brauer, M. Brodmann, T. Cahill, J. Carapetis, A. Catapano, S. Chugh, Leslie Cooper, J. Coresh, M. Criqui, Nicole DeCleene, K. Eagle, Sophia Emmons-Bell, V. Feigin, J. Fernandez-Solà, G. Fowkes, E. Gakidou, S. Grundy, F. He, G. Howard, F. Hu, L. Inker, G. Karthikeyan, N. Kassebaum, W. Koroshetz, C. Lavie, D. Lloyd-Jones, Hongmin Lu, A. Mirijello, A. Temesgen, A. Mokdad, Andrew Moran, P. Muntner, J. Narula, Bruce Neal, M. Ntsekhe, G. Oliveira, C. Otto, M. Owolabi, M. Pratt, S. Rajagopalan, M. Reitsma, A. Ribeiro, N. Rigotti, A. Rodgers, C. Sable, Saate Shakil, K. Sliwa-Hahnle, Benjamin Stark, J. Sundström, P. Timpel, I. Tleyjeh, M. Valgimigli, T. Vos, P. Whelton, Magdi Yacoub, L. Zuhlke, C. Murray, V. Fuster (2020)
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019Journal of the American College of Cardiology, 76
C. January, L. Wann, H. Calkins, Lin Chen, Joaquin Cigarroa, Joseph Cleveland, P. Ellinor, M. Ezekowitz, Michael Field, K. Furie, P. Heidenreich, Katherine Murray, Julie Shea, C. Tracy, C. Yancy (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart rhythm
A. Leow, C. Sia, B. Tan, J. Loh (2018)
A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombusJournal of Thrombosis and Thrombolysis, 46
T. Chao, Chia-Jen Liu, Ta-Chuan Tuan, Tzeng-Ji Chen, M. Hsieh, G. Lip, Shih‐Ann Chen (2017)
Lifetime Risks, Projected Numbers, and Adverse Outcomes in Asian Patients With Atrial Fibrillation: A Report From the Taiwan Nationwide AF Cohort StudyChest, 153
F. Cerini, Javier González, F. Torres, Á. Puente, M. Casas, C. Vinaixa, M. Berenguer, A. Ardèvol, S. Augustin, E. Llop, M. Senosiáin, C. Villanueva, J. Peña, R. Bañares, J. Genescà, J. Sopeña, A. Albillos, J. Bosch, V. Hernández-Gea, J. García‐Pagán (2015)
Impact of anticoagulation on upper‐gastrointestinal bleeding in cirrhosis. A retrospective multicenter studyHepatology, 62
E. Hoolwerf, N. Kraaijpoel, H. Büller, N. Es (2018)
Direct oral anticoagulants in patients with liver cirrhosis: A systematic review.Thrombosis research, 170
C. January, L. Wann, Joseph Alpert, H. Calkins, Joaquin Cigarroa, Joseph Cleveland, Jamie Conti, P. Ellinor, M. Ezekowitz, Michael Field, Katherine Murray, Ralph Sacco, William Stevenson, Patrick Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation, 130 23
R. Giugliano, C. Ruff, E. Braunwald, S. Murphy, S. Wiviott, J. Halperin, A. Waldo, M. Ezekowitz, J. Weitz, J. Špinar, W. Rużyłło, M. Ruda, Y. Koretsune, Joshua Betcher, M. Shi, L. Grip, Shirali Patel, Indravadan Patel, J. Hanyok, M. Mercuri, E. Antman (2013)
Edoxaban versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 369 22
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
L. Turco, E. Raucourt, D. Valla, E. Villa (2019)
Anticoagulation in the cirrhotic patientJHEP Reports, 1
G. Wells, G. Wells, B. Shea, B. Shea, Dianne O'Connell, J. Peterson, Welch, M. Losos, P. Tugwell, Sb Ga, G. Zello, J. Petersen (2014)
The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
CB Granger (2011)
10.1056/NEJMoa1107039N Engl J Med., 365
C. Ruff, R. Giugliano, E. Braunwald, Elaine Hoffman, Naveen Deenadayalu, M. Ezekowitz, A. Camm, J. Weitz, Basil Lewis, A. Parkhomenko, T. Yamashita, E. Antman (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 383
MR Patel (2011)
10.1056/NEJMoa1009638N Engl J Med., 365
(2020)
Review Manager (RevMan) [Computer program]. Version 5.4, The Cochrane Collaboration
M. Orso, I. Abraha, A. Mengoni, Fabrizio Taborchi, M. Giorgi, D. Franchini, P. Eusebi, Anna Heymann, A. Montedori, G. Ambrosio, Francesco Cozzolino (2020)
Accuracy of ICD-9 codes in identifying patients with peptic ulcer and gastrointestinal hemorrhage in the regional healthcare administrative database of UmbriaPLoS ONE, 15
G. Hindricks, T. Potpara, N. Dagres, E. Arbelo, Jeroen Bax, C. Blomström-Lundqvist, G. Boriani, M. Castellà, G. Dan, P. Dilaveris, L. Fauchier, G. Filippatos, J. Kalman, M. Meir, D. Lane, J. Lebeau, M. Lettino, G. Lip, F. Pinto, G. Thomas, M. Valgimigli, I. Gelder, B. putte, C. Watkins (2020)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).European heart journal
C. Granger, J. Alexander, J. McMurray, R. Lopes, E. Hylek, M. Hanna, H. Al-Khalidi, J. Ansell, D. Atar, Á. Avezum, M. Bahit, R. Diaz, J. Easton, J. Ezekowitz, G. Flaker, D. Garcia, M. Geraldes, B. Gersh, S. Golitsyn, S. Goto, A. Hermosillo, S. Hohnloser, J. Horowitz, Puneet Mohan, P. Janský, B. Lewis, J. López-Sendón, P. Pais, A. Parkhomenko, F. Verheugt, Jun Zhu, L. Wallentin (2013)
Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trialEuropean Heart Journal, 34
BackgroundPatients with atrial fibrillation (AF) have a higher risk of developing thromboembolic events. Current guidelines recommend the use of oral anticoagulants for stroke prevention in these patients. Several clinical trials demonstrated that direct oral anticoagulants (DOACs) have similar efficacy and are safer alternatives to traditional oral anticoagulants. However, patients with concomitant liver cirrhosis were excluded from these trials.ObjectiveWe aimed to systematically identify and review published clinical studies on the use of DOACs in patients with AF and liver cirrhosis and assess the efficacy and safety of DOACs in these patients.MethodsA systematic review of clinical trials and retrospective studies was conducted by searching the PubMed, Cochrane Library, Embase, SCOPUS, and Web of Science databases up to September 2020.ResultsThree retrospective studies were included, involving 4011 patients with AF and liver cirrhosis. The use of DOACs was associated with a significant reduction in ischemic stroke (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.42–0.90; p = 0.01), major bleeding events (HR 0.64; 95% CI 0.57–0.72; p < 0.001), and intracranial hemorrhage (HR 0.49; 95% CI 0.40–0.59; p < 0.001).ConclusionsCompared with warfarin in patients with AF and liver cirrhosis, DOACs appear to be associated with improved efficacy and safety outcomes. Randomized controlled trials are warranted to confirm these findings.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Mar 1, 2022
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.